Neuroprotection by aspirin and sodium salicylate through blockade of NF- κB activation

Science

Volumn 274, Issue 5291, 1996, Pages 1383-1385

  Grilli, Mariagrazia ^a   Pizzi, Marina ^a   Memo, Maurizio ^a   Spano, PierFranco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM ION; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; SALICYLATE SODIUM;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; GRANULE CELL; HIPPOCAMPUS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ASPIRIN; CALCIUM; CELL SURVIVAL; CELLS, CULTURED; CEREBELLUM; DENTATE GYRUS; GLUTAMIC ACID; HIPPOCAMPUS; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM SALICYLATE; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

ANIMALIA;

EID: 0029799831     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.274.5291.1383     Document Type: Article

References (30)

1. S. A. Lipton and P. A. Rosenberg, N. Engl. J. Med. 330, 613 (1995); M. Memo, M. Pizzi, A. Valerio, M. Grilli, P. F. Spano, Int. Rev. Psychiatry 7, 339 (1995).
2. S. A. Lipton and P. A. Rosenberg, N. Engl. J. Med. 330, 613 (1995); M. Memo, M. Pizzi, A. Valerio, M. Grilli, P. F. Spano, Int. Rev. Psychiatry 7, 339 (1995).
3. P. L. McGeer and E. G. McGeer, Brain Res Rev. 21, 195 (1995).
4. P. Insel, in Goodman and Gilman's The Pharmacological Basis of Therapeutics J. G. Hardman, P. B. Molinoff, R. W. Rudden, A. Goodman Gilman, Eds. (McGraw-Hill, New York, 1996), pp. 617-657; K. D. Rainsford, in Aspirin and the Salicylates (Butterworths, London, 1984); G. Weismann, Sci. Am. 84, 264 (January 1991); J. P. Famaey and H. E. Paulus, Eds., Therapeutic Applications of NSAIDS Subpopulations and New Formulations (Dekker, New York, 1992).
5. P. Insel, in Goodman and Gilman's The Pharmacological Basis of Therapeutics J. G. Hardman, P. B. Molinoff, R. W. Rudden, A. Goodman Gilman, Eds. (McGraw-Hill, New York, 1996), pp. 617-657; K. D. Rainsford, in Aspirin and the Salicylates (Butterworths, London, 1984); G. Weismann, Sci. Am. 84, 264 (January 1991); J. P. Famaey and H. E. Paulus, Eds., Therapeutic Applications of NSAIDS Subpopulations and New Formulations (Dekker, New York, 1992).
6. P. Insel, in Goodman and Gilman's The Pharmacological Basis of Therapeutics J. G. Hardman, P. B. Molinoff, R. W. Rudden, A. Goodman Gilman, Eds. (McGraw-Hill, New York, 1996), pp. 617-657; K. D. Rainsford, in Aspirin and the Salicylates (Butterworths, London, 1984); G. Weismann, Sci. Am. 84, 264 (January 1991); J. P. Famaey and H. E. Paulus, Eds., Therapeutic Applications of NSAIDS Subpopulations and New Formulations (Dekker, New York, 1992).
7. P. Insel, in Goodman and Gilman's The Pharmacological Basis of Therapeutics J. G. Hardman, P. B. Molinoff, R. W. Rudden, A. Goodman Gilman, Eds. (McGraw-Hill, New York, 1996), pp. 617-657; K. D. Rainsford, in Aspirin and the Salicylates (Butterworths, London, 1984); G. Weismann, Sci. Am. 84, 264 (January 1991); J. P. Famaey and H. E. Paulus, Eds., Therapeutic Applications of NSAIDS Subpopulations and New Formulations (Dekker, New York, 1992).
8. V. Gallo, M. T. Ciotti, F. Coletti, F. Aloisi, G. Levi, Proc. Natl. Acad. Sci. U.S.A. 79, 7919 (1982); M. Favaron et al., ibid. 85, 7351 (1988).
9. V. Gallo, M. T. Ciotti, F. Coletti, F. Aloisi, G. Levi, Proc. Natl. Acad. Sci. U.S.A. 79, 7919 (1982); M. Favaron et al., ibid. 85, 7351 (1988).
10. Primary cultures of cerebellar granule cells were prepared from cerebella of 8-day-old rats (Sprague-Dawley) killed according to the Policy on the Use of Animals in Neuroscience Research. The cultures were used at 10 to 12 days in vitro and contained more than 95% glutamatergic neurons. Neurotoxicity was induced as described [M. Pizzi, C. Fallacara, V Arrighi, M. Memo, P. F. Spano, J. Neurochem. 61, 683 (1993)]. Drugs tested for neuroprotection were added 5 min before and during the glutamate pulse. Cell survival was evaluated 24 hours after the glutamate pulse as described by K. H. Jones and J. A. Senft [J. Histochem. Cytochem. 33, 77 (1985)]. ASA, NaSal, and indomethacin did not affect neuronal viability per se.
11. Primary cultures of cerebellar granule cells were prepared from cerebella of 8-day-old rats (Sprague-Dawley) killed according to the Policy on the Use of Animals in Neuroscience Research. The cultures were used at 10 to 12 days in vitro and contained more than 95% glutamatergic neurons. Neurotoxicity was induced as described [M. Pizzi, C. Fallacara, V Arrighi, M. Memo, P. F. Spano, J. Neurochem. 61, 683 (1993)]. Drugs tested for neuroprotection were added 5 min before and during the glutamate pulse. Cell survival was evaluated 24 hours after the glutamate pulse as described by K. H. Jones and J. A. Senft [J. Histochem. Cytochem. 33, 77 (1985)]. ASA, NaSal, and indomethacin did not affect neuronal viability per se.
12. M. Grilli, M. Pizzi, M. Memo, P. F. Spano, data not shown.
13. 2. The percentage of cell survival was calculated by the ratio of living cells to the total number of cells.
14. D. W. Choi, J. Neurosci. 7, 369 (1987).
15. i increase without affecting glutamate-mediated calcium entry.
16. E. Kopp and S. Ghosh, Science 265, 956 (1994).
17. H. C. Liou and D. Baltimore, Curr. Opin. Cell Biol. 5, 477 (1993); M. Grilli, J.-S. Chiu, M. J. Lenardo, Int. Rev. Cytol. 143, 1 (1993).
18. H. C. Liou and D. Baltimore, Curr. Opin. Cell Biol. 5, 477 (1993); M. Grilli, J.-S. Chiu, M. J. Lenardo, Int. Rev. Cytol. 143, 1 (1993).
19. C. Kaltschmidt, B. Kaltschmidt, P. A. Baeuerle, Mech. Dev. 43, 135 (1993); C. Kattschmidt, B. Kaltschmidt, H. Neumann, H. Wekerle, P. A. Baeuerle, Mol. Cell. Biol. 14, 3981 (1994); M. Grilli et al., J. Biol. Chem. 270, 26774 (1995); S. W. Barger and M. P. Mattson, Mol. Brain Res. 40, 116 (1996).
20. C. Kaltschmidt, B. Kaltschmidt, P. A. Baeuerle, Mech. Dev. 43, 135 (1993); C. Kattschmidt, B. Kaltschmidt, H. Neumann, H. Wekerle, P. A. Baeuerle, Mol. Cell. Biol. 14, 3981 (1994); M. Grilli et al., J. Biol. Chem. 270, 26774 (1995); S. W. Barger and M. P. Mattson, Mol. Brain Res. 40, 116 (1996).
21. C. Kaltschmidt, B. Kaltschmidt, P. A. Baeuerle, Mech. Dev. 43, 135 (1993); C. Kattschmidt, B. Kaltschmidt, H. Neumann, H. Wekerle, P. A. Baeuerle, Mol. Cell. Biol. 14, 3981 (1994); M. Grilli et al., J. Biol. Chem. 270, 26774 (1995); S. W. Barger and M. P. Mattson, Mol. Brain Res. 40, 116 (1996).
22. C. Kaltschmidt, B. Kaltschmidt, P. A. Baeuerle, Mech. Dev. 43, 135 (1993); C. Kattschmidt, B. Kaltschmidt, H. Neumann, H. Wekerle, P. A. Baeuerle, Mol. Cell. Biol. 14, 3981 (1994); M. Grilli et al., J. Biol. Chem. 270, 26774 (1995); S. W. Barger and M. P. Mattson, Mol. Brain Res. 40, 116 (1996).
23. C. Kaltschmidt, B. Kaltschmidt, P. A. Baeuerle,Proc. Natl. Acad. Sci. U.S.A. 92, 9618 (1995); L. Guerrini, F. Blasi, S. Denis-Donini, ibid., p. 9077; M. Grilli, F. Goffi, M. Memo, P. F. Spano, J. Biol. Chem. 271, 15002 (1996).
24. C. Kaltschmidt, B. Kaltschmidt, P. A. Baeuerle,Proc. Natl. Acad. Sci. U.S.A. 92, 9618 (1995); L. Guerrini, F. Blasi, S. Denis-Donini, ibid., p. 9077; M. Grilli, F. Goffi, M. Memo, P. F. Spano, J. Biol. Chem. 271, 15002 (1996).
25. C. Kaltschmidt, B. Kaltschmidt, P. A. Baeuerle,Proc. Natl. Acad. Sci. U.S.A. 92, 9618 (1995); L. Guerrini, F. Blasi, S. Denis-Donini, ibid., p. 9077; M. Grilli, F. Goffi, M. Memo, P. F. Spano, J. Biol. Chem. 271, 15002 (1996).
26. T. Curran and B. R. Franza, Cell 55, 395 (1988).
27. 32P-labeled oligonucleotides in a total volume of 12 μl. Oligonucleotide sequences were as follows: ΚB oligonucleotide sequence from the immunoglobulin Κ light-chain gene, 5′-CAGAGGGGACTTTCCGAGAGGC-3′; AP-1 oligonucleotide sequence, 5′-CGCTTGATGAGTCA-GCCGGAA-3′.
28. 32P-labeled oligonucleotides in a total volume of 12 μl. Oligonucleotide sequences were as follows: ΚB oligonucleotide sequence from the immunoglobulin Κ light-chain gene, 5′-CAGAGGGGACTTTCCGAGAGGC-3′; AP-1 oligonucleotide sequence, 5′-CGCTTGATGAGTCA-GCCGGAA-3′.
29. Indomethacin (1 to 20 μM) was tested for the ability to interfere with glutamate-induced NF-ΚB activation in cerebellar granule cells. No inhibition was observed. M. Grilli, M. Pizzi, M. Memo, P. F. Spano, unpublished material.
30. This work was partially supported by Consiglio Nazionale delle Ricerche, Italy.